12:00 AM
 | 
May 24, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

KB001: Phase I/IIa data

In a double-blind, French Phase I/IIa trial in 35 mechanically ventilated patients, 33% and 46% of patients treated with 3 and 10 mg/kg IV KB001, respectively, were alive at day 28 without a P. aeruginosa infection vs. 20% for placebo (p=0.38 for...

Read the full 190 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >